Drug Approval | December 01, 2022
JB Pharma gets USFDA approval for its generic Venlafaxine Extended-Release Tablets
This product is based on Osmotic Controlled Release Oral Delivery System technology
This product is based on Osmotic Controlled Release Oral Delivery System technology
Since FY 2020 till FY 2022, the organisation has reduced energy consumption by 9.2%
Our strategy to drive therapy and brand-focused expansion will continue to show results, especially in the domestic business.
JB Pharma is the fastest growing pharmaceutical company in FY 2021-22 and Q1 of FY 2022-23.
Profit after Tax stood at Rs. 105 crore as compared to Rs. 119 crore on account of higher treasury income in Q1 FY22, non-cash ESOP cost, depreciation on account of acquired brands and finance costs in Q1 FY23
The total covered market size of four brands – Z&D, Pediclory, Pecef & Ezinapi combined is Rs 1800 crores
JB, in its new avatar, emerges as the fastest growing pharmaceuticals company in India
Ranked 25th with an impressive growth rate of 29% among Indian pharma companies in FY 2021-22
Under this initiative, 700 meals will be provided every day to four hospitals in Mumbai
Leading brands like Sporlac, Lobun, Oxalo, Pubergen, Nano-leo and Gynogen will now be part of the JBCPL franchise
Subscribe To Our Newsletter & Stay Updated
